SLCO1B3 and prostate cancer: In prostate cancer patients on androgen ablation therapy, variants of OATP1B3 with impaired function are associated with a longer progression-free and a longer overall survival, which is likely to be due to a reduced testosterone uptake into tumor cells [8, 9].